In individuals with a minimal TMB, however, ipilimumab plus nivolumab didnt give a benefit over chemotherapy, suggesting that ICI combination therapy alone is inadequate to overcome the resistance due to low immunogenicity in tumors
In individuals with a minimal TMB, however, ipilimumab plus nivolumab didnt give a benefit over chemotherapy, suggesting that ICI combination therapy alone is inadequate to overcome the resistance due to…